Northwest Biotherapeutics Files 8-K Report

Ticker: NWBO · Form: 8-K · Filed: 2025-10-14T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: NWBO

TL;DR

NWBO filed an 8-K on Oct 9th, details on 'Other Events'.

AI Summary

On October 9, 2025, Northwest Biotherapeutics, Inc. filed an 8-K report. The filing pertains to 'Other Events' and was submitted on October 14, 2025. No specific financial transactions or material events are detailed in the provided excerpt.

Why It Matters

This filing indicates a regulatory update from Northwest Biotherapeutics, Inc., which may contain information relevant to investors and stakeholders regarding the company's operations or events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial impact or significant operational changes in the provided text.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The 8-K filing is for 'Other Events' and was submitted by Northwest Biotherapeutics, Inc. on October 14, 2025, with the earliest event reported on October 9, 2025.

What is the exact name of the registrant?

The exact name of the registrant is Northwest Biotherapeutics, Inc.

In which state was Northwest Biotherapeutics, Inc. incorporated?

Northwest Biotherapeutics, Inc. was incorporated in Delaware.

What is the principal executive office address of the company?

The principal executive office address is 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.

What is the filing date of this Form 8-K?

The Form 8-K was filed as of October 14, 2025.

Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-10-14 14:22:26

Key Financial Figures

Filing Documents

01

Item 8.01. Other Events. On October 9, 2025, the Company entered into an agreement with Lead Plaintiff F. Glenn Schaeffer ("Plaintiff") for settlement of litigation pending in the Delaware Court of Chancery relating to option awards made in 2020 to Company management and directors. The agreement was set forth in a binding Term Sheet, and was the culmination of approximately a year of negotiations and a mediation in mid-September. Under the terms of the agreement, 17% of the challenged 2020 options will be cancelled, and the Company's insurance carriers will pay $2.25 million to the Company. During the mediation process, the Plaintiff filed an amended complaint (filed publicly on October 14, 2025), as the Court had directed the Plaintiff to do in an Order dated February 14, 2025. The claims set forth in the amended complaint are also covered and resolved by the settlement set forth in the Term Sheet. The parties to the litigation will use their best efforts to complete the definitive settlement documentation within thirty days. The Company understands that the Plaintiff intends to apply to the Court for an award of attorneys' fees and expenses in connection with the litigation. The settlement and any award of fees and expenses are subject to approval by the Court. Under the terms of the settlement, the cash payment to the Company from the Company's insurers is not to be used for any payment of a fee award. It is currently anticipated that the fee award will be paid separately by the Company's insurers. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: October 14, 2025 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman

View on Read The Filing